Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Pharmacol Ther. 2022 Jan 30;234:108119. doi: 10.1016/j.pharmthera.2022.108119

Table 3. Cerebral Microbleeds (CMBs) in Alzheimer’s Disease (AD) and Nondemented (ND) Subjects.

Study Age (ND) Age (AD) N (ND) N (AD) MRI Settings CMBs (ND, %) CMBs (AD, %) Fold-change (AD / ND) p value
Mean SD Mean SD
Hanyu et al. (2003) 75.6 6.6 77.3 6.5 55 59 T2* GRE (1.5 T) 7% 68% 9.32 < 0.01
Pettersen et al. (2008) - - - - 25 80 T2* GRE (1.5 T) 12% 29% 2.4 -
Brundel et al. (2012) 72 4.5 74.3 8.6 18 18 T2*GRE (7.0 T) 57% 78% 1.36 < 0.05
Goos et al. (2012) 65 6 67 6 22 52 T2* GRE (3.0 T) 0% 50% - -
Uetani et al. (2013) 54 108 6 24 75 71 SWI (3.0 T) 48% 22% 0.46 <
0.001
Kester et al. (2014) 254 293 194 143 67 59 T2* GRE (1.0, 1.5, 3.0 T) 21% 14% 0.67 < 0.05
Yates et al. (2014) 74.2 7.3 74.6 8.4 97 40 SWI (3.0 T) 22% 43% 1.96 < 0.05
Nasagawa et al. (2014) 59 9 67 8 337 547 T2* GRE (1.5 T) 14% 21% 1.53 -
Doi et al. (2015) - - - - 18 72 SWI (3.0 T) 13% 33% 2.67 < 0.05
Duits et al. (2015) 65 6 67 6 26 52 T2* GRE (3.0 T) 0% 50% - -
GRE: Gradient Echo MRI SWI : Susceptibility-weighted Imaging